Localized delivery of therapeutic doxorubicin dose across the canine blood-brain barrier with hyperthermia and temperature sensitive liposomes

Most drugs cannot penetrate the blood-brain barrier (BBB), greatly limiting the use of anti-cancer agents for brain cancer therapy. Temperature sensitive liposomes (TSL) are nanoparticles that rapidly release the contained drug in response to hyperthermia (>40 °C). Since hyperthermia also transie...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Drug delivery Ročník 25; číslo 1; s. 973 - 984
Hlavní autoři:	Bredlau, Amy Lee, Motamarry, Anjan, Chen, Chao, McCrackin, M. A., Helke, Kris, Armeson, Kent E., Bynum, Katrina, Broome, Ann-Marie, Haemmerich, Dieter
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Taylor & Francis 01.11.2018 Taylor & Francis Ltd Taylor & Francis Group
Témata:	blood-brain barrier Brain cancer doxorubicin Drug dosages Fever Hyperthermia liposomes Microscopy thermal therapy Thermosensitive liposomes Thermosensitive liposomes hyperthermia blood–brain barrier doxorubicin thermal therapy liposomes
ISSN:	1071-7544, 1521-0464, 1521-0464
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Most drugs cannot penetrate the blood-brain barrier (BBB), greatly limiting the use of anti-cancer agents for brain cancer therapy. Temperature sensitive liposomes (TSL) are nanoparticles that rapidly release the contained drug in response to hyperthermia (>40 °C). Since hyperthermia also transiently opens the BBB, we hypothesized that localized hyperthermia can achieve drug delivery across the BBB when combined with TSL. TSL-encapsulated doxorubicin (TSL-Dox) was infused intravenously over 30 min at a dose of 0.94 mg/kg in anesthetized beagles (age ∼17 months). Following, a hyperthermia probe was placed 5-10 mm deep through one of four 3-mm skull burr holes. Hyperthermia was performed randomized for 15 or 30 min, at either 45 or 50 °C. Blood was drawn every 30 min to measure TSL-Dox pharmacokinetics. Nonsurvival studies were performed in four dogs, where brain tissue at the hyperthermia location was extracted following treatment to quantify doxorubicin uptake via high-performance liquid chromatography (HPLC) and to visualize cellular uptake via fluorescence microscopy. Survival studies for 6 weeks were performed in five dogs treated by a single hyperthermia application. Local doxorubicin delivery correlated with hyperthermia duration and ranged from 0.11 to 0.74 μg/g of brain tissue at the hyperthermia locations, with undetectable drug uptake in unheated tissue. Fluorescence microscopy demonstrated doxorubicin delivery across the BBB. Histopathology in Haematoxylin & Eosin (H&E) stained samples demonstrated localized damage near the probe. No animals in the survival group demonstrated significant neurological deficits. This study demonstrates that localized doxorubicin delivery to the brain can be facilitated by TSL-Dox with localized hyperthermia with no significant neurological deficits.
AbstractList	Most drugs cannot penetrate the blood-brain barrier (BBB), greatly limiting the use of anti-cancer agents for brain cancer therapy. Temperature sensitive liposomes (TSL) are nanoparticles that rapidly release the contained drug in response to hyperthermia (>40 °C). Since hyperthermia also transiently opens the BBB, we hypothesized that localized hyperthermia can achieve drug delivery across the BBB when combined with TSL. TSL-encapsulated doxorubicin (TSL-Dox) was infused intravenously over 30 min at a dose of 0.94 mg/kg in anesthetized beagles (age ∼17 months). Following, a hyperthermia probe was placed 5-10 mm deep through one of four 3-mm skull burr holes. Hyperthermia was performed randomized for 15 or 30 min, at either 45 or 50 °C. Blood was drawn every 30 min to measure TSL-Dox pharmacokinetics. Nonsurvival studies were performed in four dogs, where brain tissue at the hyperthermia location was extracted following treatment to quantify doxorubicin uptake via high-performance liquid chromatography (HPLC) and to visualize cellular uptake via fluorescence microscopy. Survival studies for 6 weeks were performed in five dogs treated by a single hyperthermia application. Local doxorubicin delivery correlated with hyperthermia duration and ranged from 0.11 to 0.74 μg/g of brain tissue at the hyperthermia locations, with undetectable drug uptake in unheated tissue. Fluorescence microscopy demonstrated doxorubicin delivery across the BBB. Histopathology in Haematoxylin & Eosin (H&E) stained samples demonstrated localized damage near the probe. No animals in the survival group demonstrated significant neurological deficits. This study demonstrates that localized doxorubicin delivery to the brain can be facilitated by TSL-Dox with localized hyperthermia with no significant neurological deficits. Most drugs cannot penetrate the blood-brain barrier (BBB), greatly limiting the use of anti-cancer agents for brain cancer therapy. Temperature sensitive liposomes (TSL) are nanoparticles that rapidly release the contained drug in response to hyperthermia (>40 °C). Since hyperthermia also transiently opens the BBB, we hypothesized that localized hyperthermia can achieve drug delivery across the BBB when combined with TSL. TSL-encapsulated doxorubicin (TSL-Dox) was infused intravenously over 30 min at a dose of 0.94 mg/kg in anesthetized beagles (age ∼17 months). Following, a hyperthermia probe was placed 5-10 mm deep through one of four 3-mm skull burr holes. Hyperthermia was performed randomized for 15 or 30 min, at either 45 or 50 °C. Blood was drawn every 30 min to measure TSL-Dox pharmacokinetics. Nonsurvival studies were performed in four dogs, where brain tissue at the hyperthermia location was extracted following treatment to quantify doxorubicin uptake via high-performance liquid chromatography (HPLC) and to visualize cellular uptake via fluorescence microscopy. Survival studies for 6 weeks were performed in five dogs treated by a single hyperthermia application. Local doxorubicin delivery correlated with hyperthermia duration and ranged from 0.11 to 0.74 μg/g of brain tissue at the hyperthermia locations, with undetectable drug uptake in unheated tissue. Fluorescence microscopy demonstrated doxorubicin delivery across the BBB. Histopathology in Haematoxylin & Eosin (H&E) stained samples demonstrated localized damage near the probe. No animals in the survival group demonstrated significant neurological deficits. This study demonstrates that localized doxorubicin delivery to the brain can be facilitated by TSL-Dox with localized hyperthermia with no significant neurological deficits.Most drugs cannot penetrate the blood-brain barrier (BBB), greatly limiting the use of anti-cancer agents for brain cancer therapy. Temperature sensitive liposomes (TSL) are nanoparticles that rapidly release the contained drug in response to hyperthermia (>40 °C). Since hyperthermia also transiently opens the BBB, we hypothesized that localized hyperthermia can achieve drug delivery across the BBB when combined with TSL. TSL-encapsulated doxorubicin (TSL-Dox) was infused intravenously over 30 min at a dose of 0.94 mg/kg in anesthetized beagles (age ∼17 months). Following, a hyperthermia probe was placed 5-10 mm deep through one of four 3-mm skull burr holes. Hyperthermia was performed randomized for 15 or 30 min, at either 45 or 50 °C. Blood was drawn every 30 min to measure TSL-Dox pharmacokinetics. Nonsurvival studies were performed in four dogs, where brain tissue at the hyperthermia location was extracted following treatment to quantify doxorubicin uptake via high-performance liquid chromatography (HPLC) and to visualize cellular uptake via fluorescence microscopy. Survival studies for 6 weeks were performed in five dogs treated by a single hyperthermia application. Local doxorubicin delivery correlated with hyperthermia duration and ranged from 0.11 to 0.74 μg/g of brain tissue at the hyperthermia locations, with undetectable drug uptake in unheated tissue. Fluorescence microscopy demonstrated doxorubicin delivery across the BBB. Histopathology in Haematoxylin & Eosin (H&E) stained samples demonstrated localized damage near the probe. No animals in the survival group demonstrated significant neurological deficits. This study demonstrates that localized doxorubicin delivery to the brain can be facilitated by TSL-Dox with localized hyperthermia with no significant neurological deficits.
Author	Armeson, Kent E. Motamarry, Anjan Bynum, Katrina Bredlau, Amy Lee Chen, Chao Helke, Kris McCrackin, M. A. Broome, Ann-Marie Haemmerich, Dieter
Author_xml	– sequence: 1 givenname: Amy Lee surname: Bredlau fullname: Bredlau, Amy Lee organization: Department of Pediatrics, Medical University of South Carolina – sequence: 2 givenname: Anjan surname: Motamarry fullname: Motamarry, Anjan organization: Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina – sequence: 3 givenname: Chao surname: Chen fullname: Chen, Chao organization: Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina – sequence: 4 givenname: M. A. surname: McCrackin fullname: McCrackin, M. A. organization: Department of Comparative Medicine, Medical University of South Carolina – sequence: 5 givenname: Kris surname: Helke fullname: Helke, Kris organization: Department of Comparative Medicine, Medical University of South Carolina – sequence: 6 givenname: Kent E. surname: Armeson fullname: Armeson, Kent E. organization: Department of Public Health Sciences, Medical University of South Carolina – sequence: 7 givenname: Katrina surname: Bynum fullname: Bynum, Katrina organization: College of Charleston – sequence: 8 givenname: Ann-Marie surname: Broome fullname: Broome, Ann-Marie organization: Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina – sequence: 9 givenname: Dieter orcidid: 0000-0003-1127-7024 surname: Haemmerich fullname: Haemmerich, Dieter email: haemmer@musc.edu organization: Department of Pediatrics, Medical University of South Carolina
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/29688083$$D View this record in MEDLINE/PubMed
BookMark	eNqFksluFDEQhlsoiCzwCCBLXLj0YLvtHreQEChiiRSJC5wtL9UZj9z2YHcnDA_BM-OeBZEc4ORS-au_yq7_vDoJMUBVPSd4QbDArwlekiVnbEExEQvCWkIFflSdEU5JjVnLTkpcmHqGTqvznNcYY0Eof1Kd0q4VAovmrPp1HY3y7idYZMG7W0hbFHs0riCpDUyjM8jGHzFN2hkXSpwBKZNizjODjAouANI-RlvrpAqiVUoOErpz4wqtthtIs9jgFFLBohGGklHjlABlCNmNpSfybhNzHCA_rR73ymd4djgvqm8fP3y9_Fxff_l0dfn-ujZciLHWbU95w3XHem4t7wSzBBqm-15xizvLNANhGTbQYcEpB9wxzjAFoVuMqW4uqqu9ro1qLTfJDSptZVRO7hIx3UiVyuM9SAEGGmO6xvSWGcK1JqbBXcf10va27YvW273WZtIDWANhTMrfE71_E9xK3sRb2WIuOGFF4NVBIMXvE-RRDi4b8F4FiFOWFDcE04aTtqAvH6DrOKVQvkpSKpZdR-iOevH3RH9GOa69AG_2wG6TCXpp3KhGF-cBnZcEy9lk8mgyOZtMHkxWqvmD6mOD_9W929e50Mc0qLuYvJWj2vqY-qSCcVk2_5b4Dcon7Hg
CitedBy_id	crossref_primary_10_3390_pharmaceutics12010069 crossref_primary_10_1016_j_ijpharm_2025_125186 crossref_primary_10_1016_j_neuropharm_2021_108738 crossref_primary_10_1208_s12249_024_02837_3 crossref_primary_10_1016_j_ijpharm_2020_119476 crossref_primary_10_1039_D2BM01572B crossref_primary_10_3390_pharmaceutics14102012 crossref_primary_10_1002_wnan_1922 crossref_primary_10_2478_aoas_2024_0106 crossref_primary_10_1016_j_addr_2021_113859 crossref_primary_10_3389_fnins_2019_01436 crossref_primary_10_1016_j_ceramint_2021_04_080 crossref_primary_10_3390_cancers15020398 crossref_primary_10_1038_s41598_021_98163_w crossref_primary_10_3390_pharmaceutics13081193 crossref_primary_10_3390_pr8050541 crossref_primary_10_1007_s40005_021_00548_6 crossref_primary_10_3390_ijms20246126 crossref_primary_10_3390_cancers11081183 crossref_primary_10_1016_j_addr_2020_02_004 crossref_primary_10_3390_jfb13030116 crossref_primary_10_1186_s11671_019_3057_0 crossref_primary_10_1007_s11060_022_03973_1 crossref_primary_10_1080_08982104_2018_1502315 crossref_primary_10_1142_S1088424620300098 crossref_primary_10_3390_cancers14051322 crossref_primary_10_1007_s11011_022_00923_8 crossref_primary_10_1002_slct_202201288 crossref_primary_10_1007_s11060_020_03557_x crossref_primary_10_1016_j_nano_2022_102554 crossref_primary_10_3390_pharmaceutics14020308 crossref_primary_10_1016_j_jconrel_2022_02_003 crossref_primary_10_3389_fphar_2023_1251917 crossref_primary_10_1007_s10924_024_03386_3 crossref_primary_10_1016_j_addr_2021_01_012 crossref_primary_10_32604_or_2024_047278
Cites_doi	10.3109/02656739609023698 10.3109/02656736.2015.1007398 10.1016/j.jvir.2011.10.018 10.1080/02656730210147295 10.1002/1097-0142(20011001)92:7<1936::AID-CNCR1712>3.0.CO;2-H 10.1023/A:1016206631006 10.1080/02656736.2017.1412504 10.1371/journal.pone.0148613 10.1248/bpb.34.1058 10.1080/02656736.2017.1319974 10.3171/2016.9.PEDS16152 10.1002/jmri.21265 10.1371/journal.pone.0139752 10.1158/1535-7163.1311.3.10 10.1016/0304-3835(87)90165-0 10.1158/0008-5472.CAN-12-1683 10.1158/1078-0432.CCR-06-0226 10.3109/02656739409009357 10.1371/journal.pone.0179131 10.1016/j.neuroscience.2009.04.004 10.1080/02656736.2016.1206630 10.3171/jns.1996.84.2.0180 10.3109/02656736.2014.991428 10.1080/02656730701854767 10.1080/02656730410001703186 10.5772/intechopen.68159 10.1016/j.drup.2015.02.002 10.1371/journal.pone.0061512 10.1371/journal.pone.0047453 10.1124/jpet.107.127704 10.1002/ijc.11703 10.1126/scitranslmed.aaf6086 10.1158/1078-0432.CCR-03-0035 10.1016/j.ultsonch.2016.11.033 10.1093/neuonc/2.1.45 10.1038/nrd1414
ContentType	Journal Article
Copyright	2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2018 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2018 The Author(s)
Copyright_xml	– notice: 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2018 – notice: 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2018 The Author(s)
DBID	0YH AAYXX CITATION NPM 3V. 7X7 7XB 88I 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. M0S M2P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA
DOI	10.1080/10717544.2018.1461280
DatabaseName	Taylor & Francis Open Access CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Science Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest Science Journals (Alumni Edition) ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic Publicly Available Content Database PubMed
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher – sequence: 4 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate	A.L. Bredlau et al
EISSN	1521-0464
EndPage	984
ExternalDocumentID	oai_doaj_org_article_8ece3cc93cfd4c15bb1c30995b7dfd6f PMC6058514 29688083 10_1080_10717544_2018_1461280 1461280
Genre	Article Journal Article
GrantInformation_xml	– fundername: Hollings Cancer Center, http://dx.doi.org/10.13039/100006806\|Hollings Cancer Center, Medical University of South CarolinaMedical University of South Carolina grantid: P30; 13 – fundername: Hollings Cancer Center, Medical University of South Carolina grantid: P30; 13 – fundername: NIH grantid: 64) – fundername: NCI NIH HHS grantid: P30 CA138313 – fundername: NCI NIH HHS grantid: R01 CA181664 – fundername: ; ; grantid: P30; 13 – fundername: ; ; grantid: 64)
GroupedDBID	--- 00X 0YH 29G 36B 4.4 53G 5GY 7X7 88I 8FI 8FJ ABDBF ABUWG ACGEJ ACGFS ACUHS ADBBV ADCVX ADRBQ ADXPE AENEX AFKRA AFKVX AJWEG ALMA_UNASSIGNED_HOLDINGS AOIJS AQTUD ARJSQ AZQEC BABNJ BCNDV BENPR BLEHA BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAP EBC EBD EBS EJD EMB EMK EMOBN EPL ESX F5P FYUFA GNUQQ GROUPED_DOAJ H13 HCIFZ HMCUK HYE HZ~ M2P M4Z MK0 O9- OK1 P2P PHGZM PHGZT PIMPY PQQKQ PROAC RPM SV3 TDBHL TFDNU TFL TFW TUS UKHRP V1S ~1N AAYXX AFFHD CITATION 0VX 5VS AALIY AAPXX ALIPV AWYRJ BVLLS CAG COF DEIEU DLVIE DTRLO M44 NPM QRXOQ 3V. 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 5PM
ID	FETCH-LOGICAL-c588t-b6f2535b94f5dd5984d1e34bffa5d09d4b4e8d40ce908525e0945402e8b6002b3
IEDL.DBID	0YH
ISICitedReferencesCount	47
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000430842800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1071-7544 1521-0464
IngestDate	Fri Oct 03 12:50:31 EDT 2025 Tue Nov 04 01:57:42 EST 2025 Sun Nov 09 12:13:35 EST 2025 Tue Oct 07 05:39:06 EDT 2025 Thu Apr 03 07:02:52 EDT 2025 Sat Nov 29 03:37:56 EST 2025 Tue Nov 18 22:31:39 EST 2025 Mon Oct 20 23:48:41 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Thermosensitive liposomes hyperthermia blood–brain barrier doxorubicin thermal therapy liposomes
Language	English
License	open-access: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c588t-b6f2535b94f5dd5984d1e34bffa5d09d4b4e8d40ce908525e0945402e8b6002b3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0003-1127-7024
OpenAccessLink	https://www.tandfonline.com/doi/abs/10.1080/10717544.2018.1461280
PMID	29688083
PQID	2287991216
PQPubID	52922
PageCount	12
ParticipantIDs	proquest_miscellaneous_2031023516 crossref_primary_10_1080_10717544_2018_1461280 proquest_journals_2287991216 pubmed_primary_29688083 doaj_primary_oai_doaj_org_article_8ece3cc93cfd4c15bb1c30995b7dfd6f pubmedcentral_primary_oai_pubmedcentral_nih_gov_6058514 crossref_citationtrail_10_1080_10717544_2018_1461280 informaworld_taylorfrancis_310_1080_10717544_2018_1461280
PublicationCentury	2000
PublicationDate	2018-Nov
PublicationDateYYYYMMDD	2018-11-01
PublicationDate_xml	– month: 11 year: 2018 text: 2018-Nov
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England – name: Philadelphia
PublicationTitle	Drug delivery
PublicationTitleAlternate	Drug Deliv
PublicationYear	2018
Publisher	Taylor & Francis Taylor & Francis Ltd Taylor & Francis Group
Publisher_xml	– name: Taylor & Francis – name: Taylor & Francis Ltd – name: Taylor & Francis Group
References	CIT0030 CIT0010 CIT0032 CIT0031 CIT0012 CIT0034 CIT0011 CIT0033 CIT0014 CIT0036 CIT0013 CIT0016 Needham D (CIT0028) 2000; 60 CIT0038 CIT0015 CIT0037 Chen Q (CIT0007) 2004; 3 CIT0018 CIT0017 CIT0039 CIT0019 Stan AC (CIT0035) 1999; 19 CIT0040 Wu SK (CIT0041) 2014; 9 CIT0021 CIT0042 CIT0001 CIT0023 CIT0022 CIT0003 CIT0025 CIT0002 Kneidl B (CIT0020) 2014; 9 CIT0024 CIT0005 CIT0027 CIT0004 CIT0026 CIT0029 CIT0006 CIT0009 CIT0008 17947497 - J Pharmacol Exp Ther. 2008 Jan;324(1):95-102 11745268 - Cancer. 2001 Oct 1;92(7):1936-42 3677056 - Cancer Lett. 1987 Oct 30;37(2):213-24 26910903 - PLoS One. 2016 Feb 24;11(2):e0148613 25258529 - Int J Nanomedicine. 2014 Sep 16;9:4387-98 14961585 - Int J Cancer. 2004 Apr 10;109(3):442-8 21720013 - Biol Pharm Bull. 2011;34(7):1058-64 25766387 - Int J Hyperthermia. 2015 Feb;31(1):67-73 8584472 - Pharm Res. 1995 Oct;12(10):1407-16 15486198 - Mol Cancer Ther. 2004 Oct;3(10):1311-7 15041738 - Clin Cancer Res. 2004 Mar 15;10(6):2168-78 25791797 - Drug Resist Updat. 2015 Mar;19:1-12 23082168 - PLoS One. 2012;7(10):e47453 15370816 - Int J Hyperthermia. 2004 Sep;20(6):595-605 12623642 - Int J Hyperthermia. 2003 Mar-Apr;19(2):204-12 23637844 - PLoS One. 2013 Apr 29;8(4):e61512 25703389 - Int J Hyperthermia. 2015 May;31(3):285-91 28291423 - J Neurosurg Pediatr. 2017 May;19(5):518-530 22952218 - Cancer Res. 2012 Nov 1;72(21):5566-75 18219673 - J Magn Reson Imaging. 2008 Feb;27(2):376-90 22178041 - J Vasc Interv Radiol. 2012 Feb;23(2):248-55.e7 28604815 - PLoS One. 2017 Jun 12;12(6):e0179131 8592219 - J Neurosurg. 1996 Feb;84(2):180-4 18608573 - Int J Hyperthermia. 2008 Sep;24(6):475-82 11302254 - Neuro Oncol. 2000 Jan;2(1):45-59 8676003 - Int J Hyperthermia. 1996 Jan-Feb;12(1):157-65 19362131 - Neuroscience. 2009 Jul 7;161(3):926-39 15173839 - Nat Rev Drug Discov. 2004 Jun;3(6):499-508 28540820 - Int J Hyperthermia. 2018 Feb;34(1):101-111 26431204 - PLoS One. 2015 Oct 02;10(10):e0139752 28069201 - Ultrason Sonochem. 2017 May;36:198-205 10728674 - Cancer Res. 2000 Mar 1;60(5):1197-201 27431040 - Int J Hyperthermia. 2017 Feb;33(1):74-82 7963810 - Int J Hyperthermia. 1994 Jul-Aug;10(4):553-61 10368637 - Anticancer Res. 1999 Mar-Apr;19(2A):941-50 16818699 - Clin Cancer Res. 2006 Jul 1;12(13):4004-10
References_xml	– ident: CIT0017 doi: 10.3109/02656739609023698 – ident: CIT0039 doi: 10.3109/02656736.2015.1007398 – ident: CIT0040 doi: 10.1016/j.jvir.2011.10.018 – ident: CIT0025 doi: 10.1080/02656730210147295 – ident: CIT0009 doi: 10.1002/1097-0142(20011001)92:7<1936::AID-CNCR1712>3.0.CO;2-H – volume: 60 start-page: 1197 year: 2000 ident: CIT0028 publication-title: Cancer Res – ident: CIT0011 doi: 10.1023/A:1016206631006 – ident: CIT0003 doi: 10.1080/02656736.2017.1412504 – ident: CIT0022 doi: 10.1371/journal.pone.0148613 – ident: CIT0013 doi: 10.1248/bpb.34.1058 – ident: CIT0010 doi: 10.1080/02656736.2017.1319974 – ident: CIT0033 doi: 10.3171/2016.9.PEDS16152 – ident: CIT0030 doi: 10.1002/jmri.21265 – ident: CIT0036 doi: 10.1371/journal.pone.0139752 – volume: 3 start-page: 1311 year: 2004 ident: CIT0007 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.1311.3.10 – ident: CIT0029 doi: 10.1016/0304-3835(87)90165-0 – volume: 19 start-page: 941 year: 1999 ident: CIT0035 publication-title: Anticancer Res – ident: CIT0024 doi: 10.1158/0008-5472.CAN-12-1683 – ident: CIT0015 doi: 10.1158/1078-0432.CCR-06-0226 – ident: CIT0016 doi: 10.3109/02656739409009357 – ident: CIT0031 doi: 10.1371/journal.pone.0179131 – ident: CIT0019 doi: 10.1016/j.neuroscience.2009.04.004 – volume: 9 start-page: 4387 year: 2014 ident: CIT0020 publication-title: Int J Nanomedicine – ident: CIT0026 doi: 10.1080/02656730210147295 – ident: CIT0008 doi: 10.1080/02656736.2016.1206630 – ident: CIT0018 doi: 10.3171/jns.1996.84.2.0180 – ident: CIT0032 doi: 10.3109/02656736.2014.991428 – volume: 9 start-page: 4485 year: 2014 ident: CIT0041 publication-title: Int J Nanomed – ident: CIT0006 doi: 10.1080/02656730701854767 – ident: CIT0001 doi: 10.1080/02656730410001703186 – ident: CIT0027 doi: 10.5772/intechopen.68159 – ident: CIT0037 doi: 10.1016/j.drup.2015.02.002 – ident: CIT0038 doi: 10.1371/journal.pone.0061512 – ident: CIT0005 – ident: CIT0012 doi: 10.1371/journal.pone.0047453 – ident: CIT0034 doi: 10.1124/jpet.107.127704 – ident: CIT0002 doi: 10.1002/ijc.11703 – ident: CIT0004 doi: 10.1126/scitranslmed.aaf6086 – ident: CIT0023 doi: 10.1158/1078-0432.CCR-03-0035 – ident: CIT0042 doi: 10.1016/j.ultsonch.2016.11.033 – ident: CIT0014 doi: 10.1093/neuonc/2.1.45 – ident: CIT0021 doi: 10.1038/nrd1414 – reference: 28540820 - Int J Hyperthermia. 2018 Feb;34(1):101-111 – reference: 22952218 - Cancer Res. 2012 Nov 1;72(21):5566-75 – reference: 25791797 - Drug Resist Updat. 2015 Mar;19:1-12 – reference: 25766387 - Int J Hyperthermia. 2015 Feb;31(1):67-73 – reference: 28604815 - PLoS One. 2017 Jun 12;12(6):e0179131 – reference: 16818699 - Clin Cancer Res. 2006 Jul 1;12(13):4004-10 – reference: 25258529 - Int J Nanomedicine. 2014 Sep 16;9:4387-98 – reference: 15486198 - Mol Cancer Ther. 2004 Oct;3(10):1311-7 – reference: 21720013 - Biol Pharm Bull. 2011;34(7):1058-64 – reference: 11745268 - Cancer. 2001 Oct 1;92(7):1936-42 – reference: 15370816 - Int J Hyperthermia. 2004 Sep;20(6):595-605 – reference: 19362131 - Neuroscience. 2009 Jul 7;161(3):926-39 – reference: 26910903 - PLoS One. 2016 Feb 24;11(2):e0148613 – reference: 8676003 - Int J Hyperthermia. 1996 Jan-Feb;12(1):157-65 – reference: 7963810 - Int J Hyperthermia. 1994 Jul-Aug;10(4):553-61 – reference: 23637844 - PLoS One. 2013 Apr 29;8(4):e61512 – reference: 27431040 - Int J Hyperthermia. 2017 Feb;33(1):74-82 – reference: 18608573 - Int J Hyperthermia. 2008 Sep;24(6):475-82 – reference: 14961585 - Int J Cancer. 2004 Apr 10;109(3):442-8 – reference: 28069201 - Ultrason Sonochem. 2017 May;36:198-205 – reference: 3677056 - Cancer Lett. 1987 Oct 30;37(2):213-24 – reference: 23082168 - PLoS One. 2012;7(10):e47453 – reference: 18219673 - J Magn Reson Imaging. 2008 Feb;27(2):376-90 – reference: 15041738 - Clin Cancer Res. 2004 Mar 15;10(6):2168-78 – reference: 10368637 - Anticancer Res. 1999 Mar-Apr;19(2A):941-50 – reference: 8584472 - Pharm Res. 1995 Oct;12(10):1407-16 – reference: 8592219 - J Neurosurg. 1996 Feb;84(2):180-4 – reference: 26431204 - PLoS One. 2015 Oct 02;10(10):e0139752 – reference: 22178041 - J Vasc Interv Radiol. 2012 Feb;23(2):248-55.e7 – reference: 11302254 - Neuro Oncol. 2000 Jan;2(1):45-59 – reference: 17947497 - J Pharmacol Exp Ther. 2008 Jan;324(1):95-102 – reference: 12623642 - Int J Hyperthermia. 2003 Mar-Apr;19(2):204-12 – reference: 15173839 - Nat Rev Drug Discov. 2004 Jun;3(6):499-508 – reference: 10728674 - Cancer Res. 2000 Mar 1;60(5):1197-201 – reference: 28291423 - J Neurosurg Pediatr. 2017 May;19(5):518-530 – reference: 25703389 - Int J Hyperthermia. 2015 May;31(3):285-91
SSID	ssj0008125
Score	2.3810737
Snippet	Most drugs cannot penetrate the blood-brain barrier (BBB), greatly limiting the use of anti-cancer agents for brain cancer therapy. Temperature sensitive... Most drugs cannot penetrate the blood–brain barrier (BBB), greatly limiting the use of anti-cancer agents for brain cancer therapy. Temperature sensitive...
SourceID	doaj pubmedcentral proquest pubmed crossref informaworld
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	973
SubjectTerms	blood-brain barrier Brain cancer doxorubicin Drug dosages Fever Hyperthermia liposomes Microscopy thermal therapy Thermosensitive liposomes
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYl5NBLafrcNi0qlJzixrYkWzo2paGHEPaQltyE9SKGjR3s3dLNqT-hkH-YX9IZPza7obCX3owsLx7N7Mw31ugbQj56Jb2yVkRFakPEZeYiBXE-CpnImROQU3R9yH6c5mdn8uJCTddafWFNWE8P3C_ckfTWM2sVs8FxmwhjEssA1giTu-CygN43ztWYTA0-GMKW6KsNkwgp3sazOzI-wjEcwrIuiY4CPHS8EZU68v4H1KX_AqAP6yjXAtPJU_JkQJT0cy_JHnnkq2fkYNpTUi8P6fn9Cav2kB7Q6T1Z9fI5-XOKway88Y46P8MijSWtA107lkVd_atuFga34OG69bTohMA5FBQDMJV25e93v28NNpygpmiwDx7Fb7z0EhLdBn_uqixoUTmKZFgDkzNtsXweHS6dldd1W1_59gX5fvL1_Mu3aOjSEFkh5TwyWUgFE0bxIJwTSnKXeMZNCIVwsXLccC8dj61XAO9S4SGhBJiYemlwT9Cwl2Snqiv_mtBYGkBgmTNMBF6I2Pi8yCCEuljEiZXZhPBRS9oOFObYSWOmk4HpdFSuRuXqQbkT8mn12HXP4bHtgWM0gdVkpODuBsAw9WCYepthTohaNyA9777AhL5dimZbXmB_tDY9-JRWp5DcAppPE1iHD6vb4A1wi6eofL2AOcj0mjKBc171xrmSIlUZOGvJJiTfMNsNMTfvVOVlxziOe-eArN_8j3V5Sx6jqP15zn2yM28W_h3ZtT_nZdu87_7GfwE7o01_ priority: 102 providerName: Directory of Open Access Journals – databaseName: Science Database dbid: M2P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LjtMwFLVgYMGG9yMwICOhWU2YJI5Te4UAMWIxjLoY0Oyi-MVE6iQlaRFlxScg8Yd8CfcmTtqOELNgVzlOFTen5x7b1-cS8sJKYaXWPCwS7cJUZCaUEOdDl_EJMxzmFF0dsk9Hk-NjcXoqp37BrfVplQMndkRtao1r5AcJSHvQMkmcvZp_CbFqFO6u-hIaV8k1UDYxpnR9SKYjE0Pw4n3OYRyi0dtwgkdEB9iGTZjcJZAugKejrdjUWfhfMDD9mwy9mE25EZ4Ob_3vwG6Tm16Y0tc9ku6QK7a6S_amvbP1ap-erA9qtft0j07Xntere-TnEcbE8rs11NgZ5nqsaO3oxukuaupvdbNUuJMPn1tLi-5XwD4U3i-oXdpl0f_-8Uth3QqqigbL6VFcKqZnMF9u8OvOy4IWlaHoqeUNoWmLWfjI23RWzuu2PrftffLx8N3J2_ehL_YQai7EIlSZSzjjSqaOG8OlSE1sWaqcK7iJpElVaoVJI20lqMSEW5iXgtpMrFC4tajYA7JT1ZV9RGgkFAi5zCjGXVrwSNlJkUEkNhGPYi2ygKTDa861d0LHghyzPPaGqQM6ckRH7tERkJfjbfPeCuSyG94ghsbO6OTdNdTN59wTQy6stkxrybQzqY65UrFmINu5mhhnMhcQuYnAfNEt5Li-6krOLnmA3QFyuaemNl_jLSDPx8tAKrhTVFS2XkIfNIxNGMc-D3t0j6NIZAacL1hAJlu43xrm9pWqPOuMy3ELHgT6438_1hNyAwfRH_jcJTuLZmmfkuv666Jsm2fdP_wP9hNZkw priority: 102 providerName: ProQuest
Title	Localized delivery of therapeutic doxorubicin dose across the canine blood-brain barrier with hyperthermia and temperature sensitive liposomes
URI	https://www.tandfonline.com/doi/abs/10.1080/10717544.2018.1461280 https://www.ncbi.nlm.nih.gov/pubmed/29688083 https://www.proquest.com/docview/2287991216 https://www.proquest.com/docview/2031023516 https://pubmed.ncbi.nlm.nih.gov/PMC6058514 https://doaj.org/article/8ece3cc93cfd4c15bb1c30995b7dfd6f
Volume	25
WOSCitedRecordID	wos000430842800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1521-0464 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008125 issn: 1071-7544 databaseCode: DOA dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1521-0464 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008125 issn: 1071-7544 databaseCode: 7X7 dateStart: 20171101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1521-0464 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008125 issn: 1071-7544 databaseCode: BENPR dateStart: 20171101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1521-0464 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008125 issn: 1071-7544 databaseCode: PIMPY dateStart: 20171101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1521-0464 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008125 issn: 1071-7544 databaseCode: M2P dateStart: 20171101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest – providerCode: PRVAWR databaseName: Taylor & Francis Journals Complete customDbUrl: eissn: 1521-0464 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008125 issn: 1071-7544 databaseCode: TFW dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 1521-0464 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008125 issn: 1071-7544 databaseCode: 0YH dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLbQxgMv3C-FURkJ7WlBSWwn9iNDq4a0VREq0D1F8Y1V6popaaeVH8Fv5pwk7doJtAd4cRvHjnLi43Oxj79DyHunpFPGiKCIjQ-4TGygQM8HPhEpswJ8iiYP2beTdDiU47HKumjCugurRB_at0ARjazGyV3oehURB7_ggwiOKyKRxKkOMha89t0YqtH_Cs-O18IY9Jdoww6jAPusDvH87TFb6qlB8b-FYfonS_R2QOWGhho8-g-0PSYPO_OUfmz56Qm552ZPyX7W4lsvD-jo5rhWfUD3aXaDfL18Rn6doGac_HSWWjfFiI8lLT3dOONFbXldVguN-_nwv3a0aD4EtqEwyvDCtI2l15i7guqiwpR6FJeL6Tn4zBU-7GJSUKCQIq5WBwpNa4zER9lNp5PLsi4vXP2cfB0cjT4dB13Ch8AIKeeBTnwsmNCKe2GtUJLbyDGuvS-EDZXlmjtpeWicAksxFg58U7A4Yyc1bi9q9oLszMqZe0VoKDUYc4nVTHheiFC7tEhAG9tQhJGRSY_w1TjnpkNDx6Qc0zzqQFNXI5HjSOTdSPTIh3W3yxYO5K4Oh8hE68aI5t1UlNWPvBMOuXTGMWMUM95yEwmtI8PAdBc6td4mvkfUJgvm82Yxx7eZV3J2xwvsrfg178RTncfgJ4NjEEfwHd6tb4Ngwd2iYubKBbRB0NiYCWzzsmXvNRWxSkDuS9Yj6Rbjb5G5fWc2OW_Ay3EbHoz01_9A0hvyAC_bE6F7ZGdeLdxbct9czSd11W_mP5TpOG1K2Se7h0fD7Eu_WW-B8jTOoC77fJqdwdVo8P03UxFh6g
linkProvider	Taylor & Francis
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLZKQYIL-zJQwEjQU0OT2M7YB4TYqlYdRnMoqDcTb3SkaTIkM8Bw4icg8T_4UfwS_LLMUiF66oFb5DhR7Hx-i_3e9xB6bAW3QmsWpLF2AeWJCYTX84FLWJcY5n2Kqg7Z-1633-eHh2Kwhn61uTAQVtnKxEpQm1zDHvl27E17b8vEUfJ8_CmAqlFwutqW0KhhsW9nX7zLVj7be-3_75M43nlz8Go3aKoKBJpxPglU4mJGmBLUMWOY4NREllDlXMpMKAxV1HJDQ22FN0diZr0D5M2a2HIFZ1iK-PeeQ-cpMItBqGA8mEt-ryxZHeMYBUAs12YM8XAb2qAJgsk4iCevF8IVXViVDDhBmPo3s_dk9OaSOty58r9N5FV0uTG88Yt6pVxDaza7jjYHNXP3bAsfLBLRyi28iQcLTu_ZDfSjBzp_-M0abOwIYllmOHd4KXsNm_xrXkwVRCr469LitJp16IM9fr01j6ssgd_ffyqoy4FVWkC5QAxb4fhoNrYFvO54mOI0Mxg4wxrCa1xClgHoJTwajvMyP7blTfTuTGbrFlrP8szeQTjkyhuqiVGEOZqyUNlumnhLw4QsjDRPOoi2sJK6YXqHgiMjGTWEsC0aJaBRNmjsoKfzx8Y11clpD7wEzM47A1N51ZAXH2Uj-CS32hKtBdHOUB0xpSJNvFvCVNc4k7gOEsuIl5Nqo8rVVWUkOeUDNlqIy0b0lnKB7w56NL_thSachKWZzae-DxDixoRBn9v1apqPIhaJ12mcdFB3ZZ2tDHP1TjY8qojZIcTAOyB3__1ZD9HF3YO3Pdnb6-_fQ5dgQHVy6wZanxRTex9d0J8nw7J4UEkXjD6c9Sr8A_9RtcQ
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQghAX3o_CAkZCe9qgJLZT-8irAlFVPRTYmxW_2EjdpEpaRPkR_GZmkrTbrkB7gFOi2I48mck87PE3hLz0SnplrYjy1IaIy8xFCux8FDIxZE5ATNHWIfsyHk4m8uRETftswqZPq8QYOnRAEa2uxp974cImIw6uEIMIjisiicRfHXQsRO1XwXXOUMhno69bZQz2S3Rph0mEYzaHeP72mj3z1KL4X8Aw_ZMnejGhcsdCjW79B9puk5u9e0pfd_J0h1zx5V1yNO3wrdfHdHZ-XKs5pkd0eo58vb5Hfo3RMhY_vaPOzzHjY02rQHfOeFFX_ajqlcH9fLhvPM3bD4F9KHAZJky7XHqDtSuoyWssqUdxuZieQsxc48vOipwChRRxtXpQaNpgJj7qbjovFlVTnfnmPvk8ej97-yHqCz5EVki5jEwWUsGEUTwI54SS3CWecRNCLlysHDfcS8dj6xV4iqnwEJuCx5l6aXB70bAH5KCsSv-I0FgacOYyZ5gIPBex8cM8A2vsYhEnVmYDwjd81rZHQ8eiHHOd9KCpG05o5ITuOTEgr7bDFh0cyGUD3qAQbTsjmnf7oKq_6V45aOmtZ9YqZoPjNhHGJJaB6y7M0AWXhQFRuyKol-1iTugqr2h2yQQON_Kqe_XU6BTiZAgM0gS-w4ttMygW3C3KS1-toA-CxqZMYJ-HnXhvqUhVBnpfsgEZ7gn-Hpn7LWVx2oKX4zY8OOmP_4Gk5-T69N1Ijz9OPj0hN7ClOxx6SA6W9co_Jdfs92XR1M9aVfAbJyFctA
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Localized+delivery+of+therapeutic+doxorubicin+dose+across+the+canine+blood-brain+barrier+with+hyperthermia+and+temperature+sensitive+liposomes&rft.jtitle=Drug+delivery&rft.au=Bredlau%2C+Amy+Lee&rft.au=Motamarry%2C+Anjan&rft.au=Chen%2C+Chao&rft.au=McCrackin%2C+M.+A.&rft.date=2018-11-01&rft.pub=Taylor+%26+Francis&rft.issn=1071-7544&rft.eissn=1521-0464&rft.volume=25&rft.issue=1&rft.spage=973&rft.epage=984&rft_id=info:doi/10.1080%2F10717544.2018.1461280&rft.externalDBID=0YH&rft.externalDocID=1461280
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1071-7544&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1071-7544&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1071-7544&client=summon